Brookline Capital Markets Expects Lower Earnings for Genelux

Genelux Corporation (NASDAQ:GNLX – Free Report) – Brookline Capital Markets cut their FY2026 earnings per share estimates for Genelux in a report issued on Monday, November 16th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings of ($0.85) per share for the year, down from their prior forecast of ($0.80). The consensus estimate for Genelux’s current full-year earnings is ($0.85) per share. Brookline Capital Markets also issued estimates for Genelux’s Q4 2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.58) EPS.

GNLX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Thursday, October 15th. Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Wall Street Zen downgraded shares of Genelux from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Lucid Cap Mkts upgraded shares of Genelux to a “strong-buy” rating in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Get Our Latest Research Report on GNLX

Genelux Stock Performance

Shares of Genelux stock opened at $2.17 on Thursday. The business’s 50 day simple moving average is $2.28 and its 200 day simple moving average is $2.64. Genelux has a 52-week low of $1.77 and a 52-week high of $5.89. The firm has a market cap of $98.17 million, a PE ratio of -2.47 and a beta of 0.68.

Genelux (NASDAQ:GNLX – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03).

Institutional Trading of Genelux

A number of hedge funds have recently modified their holdings of the stock. Woodward Diversified Capital LLC raised its holdings in Genelux by 5.2% in the 3rd quarter. Woodward Diversified Capital LLC now owns 2,378,755 shares of the company’s stock valued at $6,018,000 after acquiring an additional 116,647 shares during the period. BlackRock Inc. bought a new stake in shares of Genelux during the second quarter worth approximately $1,323,000. Bank of America Corp DE bought a new stake in shares of Genelux during the second quarter worth approximately $990,000. Flputnam Investment Management Co. bought a new stake in shares of Genelux during the second quarter worth approximately $697,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Genelux in the second quarter valued at approximately $686,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Insider Buying and Selling

In related news, insider Yong Yu sold 9,683 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.75, for a total value of $26,628.25. Following the sale, the insider owned 258,688 shares in the company, valued at approximately $711,392. This represents a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas Zindrick sold 34,463 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.67, for a total value of $92,016.21. Following the sale, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at $3,274,560.09. This represents a 2.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,903 shares of company stock worth $126,320 over the last three months. 7.50% of the stock is owned by insiders.

Genelux Company Profile

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Read More

Earnings History and Estimates for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.